Have questions?Contact Us
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
Eligibility and Recruitment Information
|Inclusion||Clinical diagnosis of Parkinson's disease. Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive.|
|Exclusion||Any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening. Clinically significant neurologic disorder other than Parkinson's disease, including history of stroke, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening.|